Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Peritoneal Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 12Cisplatin 11Hyperthermic Intraperitoneal Chemotherapy 10Cytoreduction Surgical Procedures 9Oxaliplatin 8Fluorouracil 7Mitomycin 6Carboplatin 5Leucovorin 4Bevacizumab 4catumaxomab 3Doxorubicin 3Docetaxel 3sodium thiosulfate 2Indocyanine Green 2Drug Therapy 2Cetuximab 2volociximab 1vandetanib 1relacorilant 1pasireotide 1nilotinib 1farletuzumab 1epothilone B 1enzastaurin 1birinapant 1alvimopan 1Surgical Procedures, Operative 1Saline Waters 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peritoneal Neoplasms × birinapant × Clear all
NCT01681368 2017-05-30

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
11 enrolled 19 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡